FDA OKs oral Wegovy

The Food and Drug Administration has cleared Wegovy tablets, making semaglutide the first oral glucagon-like peptide-1 pill approved in the United States for chronic weight management. (accessdata.fda.gov) Glucagon-like peptide-1 drugs mimic a gut hormone that helps people feel full and eat less. The new tablet joins the weekly Wegovy shot as a prescription option for adults with obesity, or adults with overweight plus at least one weight-related condition, alongside diet and exercise. (accessdata.fda.gov) The approval rests in part on OASIS 4, a phase 3 trial that enrolled 307 adults without diabetes and assigned 205 to oral semaglutide 25 milligrams and 102 to placebo. The treatment period lasted 64 weeks, with a total study length of 72 weeks including screening and follow-up. (clinicaltrials.gov; ajmc.com) In the main analysis, people taking the pill lost an average of 13.6% of body weight by week 64, versus 2.2% with placebo. In a separate analysis estimating results among people who stayed on treatment as assigned, average weight loss was 16.6% with oral semaglutide and 2.7% with placebo. (ajmc.com; appliedclinicaltrialsonline.com) The tablet label also gives Wegovy pills the same cardiovascular use as the injection: reducing major adverse cardiovascular events in adults with established cardiovascular disease and obesity or overweight. Those events include cardiovascular death, non-fatal heart attack, and non-fatal stroke. (accessdata.fda.gov) That matters because the obesity drug market has been dominated by injections, even as demand for simpler dosing has grown. Novo Nordisk said on December 22, 2025, that it planned a United States launch in early January 2026. (ajmc.com) The pill does not erase the tradeoffs that came with earlier semaglutide products. The prescribing information carries a boxed warning about thyroid C-cell tumors seen in rodents and says Wegovy is contraindicated in patients with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2. (accessdata.fda.gov) Stomach side effects also remained common in the trial. In the published OASIS 4 results, gastrointestinal adverse events were reported in 74.0% of participants on oral semaglutide and 42.2% on placebo. (nejm.org) Novo Nordisk and conference reports from ObesityWeek 2025 said OASIS 4 analyses also found improvements in blood sugar measures and cardiovascular risk factors, especially among participants who lost at least 15% of body weight. The company has also listed North Carolina among its production sites for the product. (appliedclinicaltrialsonline.com; prnewswire.com) For patients and doctors, the change is straightforward: the same semaglutide brand that became a weekly shot for weight loss is now also a once-daily pill. The next test is how widely it gets prescribed, covered, and tolerated in routine care. (accessdata.fda.gov; ajmc.com)